Reed John C
- SEC CIK
- 0001181561
In the past year, 2 open-market sale filings worth $17.3M and no purchases.
Current role at each company
- MDGL Madrigal Pharmaceuticals, Inc.Directoras of Aug 18, 2026
- JNJ Johnson & JohnsonEVP, Innovative Medicine, R&Das of May 4, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $17.3M
- 2 filings
- Net
- −$17.3M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Reed John C as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
JNJ Johnson & Johnson
EVP, Innovative Medicine, R&D3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 18, 2026 (view filing) | Feb 17 | 1 day | Reed John CEVP, Innovative Medicine, R&D | SSale | −53.9K | $243.00 | −$13.1M | −83.5%10.7K after | 3 lots |
| Oct 20, 2025 (view filing) | Oct 17 | 3 days | Reed John CEVP, Innovative Medicine, R&D | SSale | −21.7K | $192.71 | −$4.19M | −67.1%10.7K after | |
| Jul 18, 2025 (view filing) | Jul 17 | 1 day | Reed John CEVP, Innovative Medicine, R&D | SSale | −19.1K | $163.55 | −$3.13M | −64.2%10.7K after |